The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Are Your Patients at Risk? Advocacy Matters

Are Your Patients at Risk? Advocacy Matters

February 6, 2020 • By Kimberly Retzlaff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

When insurance company practices put patients at risk, advocacy is an important tool physicians can use to make a real difference. The ACR and its members are actively advocating for rheumatologists and patients on priority issues, including prior authorization, step therapy, drug pricing and out-of-pocket costs. By speaking up and engaging their patients, rheumatologists can help change harmful practices.

You Might Also Like
  • Patients & Physicians Unite for Arthritis Advocacy
  • The ACR Announces Advocacy Priorities for 2016
  • The ACR’s Advocacy at State Legislature Level in 2016 Focuses on Biosimilars, Step Therapy
Also By This Author
  • AMA House of Delegates Meeting Postponed Due to COVID-19, Advocacy Efforts Continue

Effects on Patient Care
Insurance company policies can negatively affect patient outcomes by delaying or altering treatment plans. Norman Gaylis, MD, the board liaison to the ACR Government Affairs Committee (GAC), sees delays in patient care at his Florida practice due to insurance requirements for prior authorization. The problem is especially pronounced early in the year, he says, because patients who change insurance plans must wait for new authorizations. In late January, numerous patients in his clinic were still waiting for treatment because their insurance companies had yet to provide authorization.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The increasing prevalence of step therapy policies is another area of concern, says Chris Phillips, MD, chair of the ACR Insurance Subcommittee (ISC) of the Committee on Rheumatologic Care. “Many of the step therapy requirements are not evidence based and oblige our members to abandon a planned treatment sequence based on clinical evidence and the provider’s experience,” he says. “And we know that opaque rebates between manufacturers and pharmacy benefit managers [PBMs] drive the tiering of drugs in these protocols.”

Step therapy policies can also lead to higher drug prices for patients. A medication required by an insurance company may be more expensive than an alternative recommended by the physician. In such cases, the patient ends up having to pay more to receive a non-recommended treatment.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

High out-of-pocket expenses are another issue for patients. At Dr. Gaylis’s practice, some patients with new out-of-pocket requirements as of 2020 are finding their biologic therapies aren’t covered, he says. Practice staff try to help patients obtain free or reduced-cost treatments through foundations that support the cost of biological prescriptions. Without such assistance, however, patients may not be able to afford treatment.

The Importance of Advocacy
Effecting real change related to current priority issues is not easy, but it is possible through advocacy efforts. And there is strength in numbers, so the more people who get involved and speak up, the better the chances of success.

“The first step in advocacy is simply recognizing that it works,” Dr. Phillips says. “Only through our collective outreach—individually, as a group within rheumatology, and in the broader house of medicine—do things get done.”

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 | Single Page

Filed Under: Legislation & Advocacy Tagged With: ACR Insurance Subcommittee (ISC), Advocacy, Brian Loggins, Chris Morris, Dr. Chris Phillips, Government Affairs Committee (GAC), Norman B. Gaylis

You Might Also Like:
  • Patients & Physicians Unite for Arthritis Advocacy
  • The ACR Announces Advocacy Priorities for 2016
  • The ACR’s Advocacy at State Legislature Level in 2016 Focuses on Biosimilars, Step Therapy
  • ACR Advocacy at the State Level in 2016

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.